Biodesix (NASDAQ:BDSX) Director Purchases $18,855.52 in Stock

Key Points

• Biodesix Director Jack Schuler purchased 3,056 shares of stock at an average price of $6.17, increasing his total ownership to approximately $7.64 million.
• The company's recent earnings results revealed a loss of ($1.60) EPS, falling short of analysts' expectations while reporting revenue of $20.02 million.
• Equities analysts have given Biodesix a consensus rating of "Moderate Buy" with an average price target of $32.50.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack W. Schuler purchased 3,056 shares of Biodesix stock in a transaction that occurred on Thursday, September 18th. The shares were bought at an average cost of $6.17 per share, for a total transaction of $18,855.52. Following the completion of the transaction, the director directly owned 1,238,700 shares in the company, valued at $7,642,779. This represents a 0.25% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Biodesix Price Performance

Biodesix stock traded up $0.02 during midday trading on Monday, hitting $7.15. 58,910 shares of the company were exchanged, compared to its average volume of 341,148. The company's fifty day moving average price is $7.99 and its 200-day moving average price is $8.82. The company has a debt-to-equity ratio of 41.11, a quick ratio of 2.14 and a current ratio of 2.14. Biodesix, Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $36.00.

Biodesix (NASDAQ:BDSX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.40) by ($0.20). The company had revenue of $20.02 million for the quarter, compared to analyst estimates of $18.47 million. Biodesix had a negative return on equity of 269.67% and a negative net margin of 53.66%. Biodesix has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Biodesix

A number of institutional investors have recently made changes to their positions in the company. Birchview Capital LP increased its holdings in shares of Biodesix by 2.8% in the 1st quarter. Birchview Capital LP now owns 5,736,113 shares of the company's stock valued at $3,586,000 after acquiring an additional 154,937 shares during the last quarter. Monashee Investment Management LLC grew its stake in Biodesix by 15.7% during the 1st quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company's stock worth $2,532,000 after buying an additional 549,121 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock worth $58,000 after purchasing an additional 102,494 shares in the last quarter. Millennium Management LLC grew its stake in shares of Biodesix by 20.2% in the fourth quarter. Millennium Management LLC now owns 198,671 shares of the company's stock worth $304,000 after purchasing an additional 33,329 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Biodesix by 286.5% in the fourth quarter. Northern Trust Corp now owns 169,132 shares of the company's stock worth $259,000 after purchasing an additional 125,368 shares in the last quarter. 20.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on BDSX. Canaccord Genuity Group set a $20.00 target price on Biodesix and gave the company a "buy" rating in a research report on Friday. Wall Street Zen raised Biodesix to a "sell" rating in a research report on Saturday, September 13th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Biodesix has a consensus rating of "Moderate Buy" and a consensus price target of $32.50.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.